CM6325, an oral CRAC channel inhibitor
CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. CM6325 is highly selective and has pharmacokinetic properties that are consistent with once-daily oral dosing with preclinical data supporting its use in chronic inflammatory conditions.
CM6325 Rheumatoid Arthritis / Chronic Pancreatitis
CalciMedica is developing CM6325, an oral CRAC channel inhibitor for chronic inflammatory conditions. Preclinical data support the use of CRAC channel inhibitors in indications such as rheumatoid arthritis, atopic dermatitis, asthma, psoriasis and chronic pancreatitis, where an intravenous formulation would be problematic. CM6325 is highly selective and has pharmacokinetic properties that are consistent with once-daily oral dosing.
CalciMedica plans on submitting an Investigational New Drug application for CM6325 in 2021 and initiating a Phase 1 trial in 2021 as well.